Esperion Announces Data from CLEAR Outcomes Sub-Groups as Poster Presentations, Moderated Session & Industry Expert Theatre to be Presented at ACC.24
25 Março 2024 - 5:00PM
Esperion (NASDAQ: ESPR) today announced the acceptance of
three CLEAR (
Cholesterol
Lowering
via B
empedoic acid, an
ACL-Inhibiting
Regimen) Outcomes
subgroup analyses as poster presentations at the 2024 American
College of Cardiology’s Annual Scientific Session (ACC.24) in
Atlanta, Georgia. Additionally, the Company will participate in a
moderated session in partnership with UT Southwestern Medical
Center, host an industry expert theatre, and have a commercial and
medical information booth during ACC.24.
"Esperion welcomes the opportunity to showcase
additional data from our pivotal CLEAR Outcomes trial at the
American College of Cardiology's Annual Scientific
Session," said JoAnne Foody, MD, Chief Medical Officer for
Esperion. "Complementing the ACC.24 theme of Cardiovascular Care
for All, we will highlight our commitment to underserved
populations and present subset analyses in women and
Hispanic/Latinx patients as well as in patients with obesity."
CLEAR Outcomes Sub-group Poster
Presentations
Title: |
Characteristics and Outcomes for Statin-Intolerant
Women Receiving Bempedoic Acid in the CLEAR Outcomes
Trial |
Session: |
1213 |
Location: |
Hall B4-5 |
Date & Time: |
4/6/24, 9:45 – 10:30 AM ET |
Speaker: |
Leslie Cho, MD; Cleveland Clinic, Cleveland, Ohio |
|
|
Title: |
Characteristics and Outcomes for
Statin-Intolerant Hispanic/Latinx Patients
Receiving Bempedoic Acid; Results from a CLEAR Outcomes
Pre-Specified Sub-Analysis |
Session: |
1294 |
Location: |
Hall B4-5 |
Date & Time: |
4/6/24,1:45 – 2:30 PM ET |
Speaker: |
Fatima Rodriguez, MD, MPH; Stanford Cardiovascular Institute,
Stanford Medicine, Stanford, California |
|
|
Title: |
Bempedoic Acid and Cardiovascular Disease Outcomes in Patients
with Obesity: A CLEAR Outcomes Subset
Analysis |
Session: Location: Date &
Time:Speaker: |
1433Hall B4-54/7/24, 1:15 – 2:00 PM ETHarold Bays, MD, FOMA,
FTOS, FACC, FNLA, FASPC; Louisville Metabolic and
Atherosclerosis Research Center, University of Louisville School of
Medicine, Louisville, Kentucky |
|
|
Moderated
Presentation |
Title:
Session: Location: Date
& Time:
Speaker: |
Impact of Payer Rejections and
Out-Of-Pocket Costs on Patient Access to Bempedoic Acid
Therapy 1092Moderated Poster Theatre 084/7/24, 3:15 – 3:25 PM
ETJimin Hwang, MD; UT Southwestern Medical Center, Dallas,
Texas |
|
|
Industry
Expert Theatre |
Title:
Location: Date
& Time:
Speaker: |
A Next Step in Cardiovascular Disease ManagementTheatre
#24/7/2024, 11:15 AM – 12:15 PM ETManesh Patel, MD Chief, Division
of Cardiology, Director Duke Heart Center |
Esperion Therapeutics
At Esperion, we discover, develop, and commercialize innovative
medicines to help improve outcomes for patients with or at risk for
cardiovascular and cardiometabolic diseases. The status quo is not
meeting the health needs of millions of people with high
cholesterol – that is why our team of passionate industry leaders
is breaking through the barriers that prevent patients from
reaching their goals. Providers are moving toward reducing
LDL-cholesterol levels as low as possible, as soon as possible; we
provide the next steps to help get patients there. Because when it
comes to high cholesterol, getting to goal is not optional. It is
our life’s work. For more information, visit esperion.com and
esperionscience.com and follow us on X at
twitter.com/EsperionInc.
CLEAR Cardiovascular Outcomes TrialCLEAR
Outcomes is part of the CLEAR clinical research program for
NEXLETOL® (bempedoic acid) Tablet and NEXLIZET® (bempedoic acid and
ezetimibe) Tablet. The CLEAR Program seeks to generate important
clinical evidence on the safety and efficacy of bempedoic acid, a
first in a class ATP citrate lyase inhibitor contained in NEXLETOL
and NEXLIZET and its potential role in addressing additional
critical unmet medical needs. More than 60,000 people will have
participated in the program by the time of its completion. The
CLEAR Program includes 5 label-enabling Phase III studies as well
as other key Phase IV studies with the potential to reach more than
70 million people with or at risk for CVD based on elevated
LDL-C.
Forward-Looking Statements
This press release contains forward-looking statements that are
made pursuant to the safe harbor provisions of the federal
securities laws, including statements regarding marketing strategy
and commercialization plans, current and planned operational
expenses, future operations, commercial products, clinical
development, including the timing, designs and plans for the CLEAR
Outcomes study and its results, plans for potential future product
candidates, financial condition and outlook, including expected
cash runway, and other statements containing the words
“anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,”
“plan,” “predict,” “project,” “suggest,” “target,” “potential,”
“will,” “would,” “could,” “should,” “continue,” and similar
expressions. Any express or implied statements contained in this
press release that are not statements of historical fact may be
deemed to be forward-looking statements. Forward-looking statements
involve risks and uncertainties that could cause Esperion’s actual
results to differ significantly from those projected, including,
without limitation, the net sales, profitability, and growth of
Esperion’s commercial products, clinical activities and results,
supply chain, commercial development and launch plans, the outcomes
and anticipated benefits of legal proceedings and settlements, and
the risks detailed in Esperion’s filings with the Securities and
Exchange Commission. Any forward-looking statements contained in
this press release speak only as of the date hereof, and Esperion
disclaims any obligation or undertaking to update or revise any
forward-looking statements contained in this press release, other
than to the extent required by law.
Esperion Contact Information:
Investors: Alexis Callahaninvestorrelations@esperion.com (406)
539-1762
Media: Tiffany Aldrich corporateteam@esperion.com (616)
443-8438
Esperion Therapeutics (NASDAQ:ESPR)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Esperion Therapeutics (NASDAQ:ESPR)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024